The effect of angiotensin-converting enzyme inhibitor exposure on coronary artery bypass grafting.
Laura M SeeseIbrahim S SultanYisi WangThomas GleasonFloyd ThomaArman KilicPublished in: Journal of cardiac surgery (2019)
This study of 5270 propensity-matched patients suggests that ACEi can safely be continued until the time of CABG without an adverse impact on clinical outcomes, and in fact, may confer an early survival advantage and reduced postoperative renal failure rates.
Keyphrases
- coronary artery bypass grafting
- angiotensin converting enzyme
- end stage renal disease
- coronary artery disease
- percutaneous coronary intervention
- angiotensin ii
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- acute coronary syndrome
- atrial fibrillation
- free survival